Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 5:12:670945.
doi: 10.3389/fphar.2021.670945. eCollection 2021.

Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service

Kristopher Amaro-Hosey  1   2 , Immaculada Danés  1   2   3 , Lourdes Vendrell  1   2   3 , Laura Alonso  3   4 , Berta Renedo  5 , Luis Gros  3   4 , Xavier Vidal  1   2   3 , Gloria Cereza  2   3   6 , Antònia Agustí  1   2   3
Affiliations

Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service

Kristopher Amaro-Hosey et al. Front Pharmacol. .

Abstract

Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology Service of a tertiary hospital. During 2017, patients exposed to one or more drugs of a previously agreed list were identified and followed-up for at least 6 months each. Characteristics of ADR, incidence, causality and possible preventability, have been evaluated. Results: 72 patients have been treated with at least one study drug, and 159 ADR episodes involving at least one of these drugs have been identified, with a total of 293 ADR. Most episodes required hospital admission (35.2%) or happened during the hospital stay (33%), and 91.2% were severe. Blood disorders were the most frequent ADR (96; 32.8%), related to thioguanine (42) and pegaspargase (39) mainly, followed by infections (86; 29.4%) related to thioguanine (32), pegaspargase (27), Erwinia asparaginase (14) and rituximab (13). Two ADR were unknown. Most ADR were dose-dependent or expectable (>90%). The global incidence of ADR was 3.1/100 days at risk (95% CI 2.7-3.5), with 3.5 ADR/100 days at risk with pegaspargase (95% CI 2.9-4.2), 1.2/100 days at risk with rituximab (95% CI 0.8-1.8) and 11.6/100 days at risk with thioguanine (95% CI 9.4-14.2). Controversial additional measures of prevention, other than those already used, were identified. Conclusion: ADR are frequent in pediatric oncohematological patients, mainly blood disorders and infectious diseases. Findings regarding incidence and preventability may be useful to compare data between different centers and to evaluate new possibilities for action or prevention.

Keywords: adverse drug reactions; hematology; incidence; neoplasms; pediatrics; pegaspargase; pharmacovigilance; thioguanine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Aaltonen K. J., Joensuu J. T., Virkki L., Sokka T., Aronen P., Relas H., et al. (2015). Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy. J. Rheumatol. 42, 372–378. 10.3899/jrheum.140853 - DOI - PubMed
    1. Agencia Española de Medicamentos y Productos Sanitarios. (2013). Medicamentos Sujetos a Un Seguimiento Adicional. Available at: http://www.aemps.gob.es/vigilancia/medicamentosUsoHumano/seguimiento_adi... (Accessed December 4, 2020).
    1. Aguirre C., García M. (2016). Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de Farmacovigilancia. Med. Clin. (Barc.) 147, 461–464. 10.1016/j.medcli.2016.06.012 - DOI - PubMed
    1. Alexander S., Fisher B. T., Gaur A. H., Dvorak C. C., Villa Luna D., Dang H., et al. (2018). Effect of Levofloxacin Prophylaxis on Bacteremia in Children with Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation. JAMA 320, 995–1004. 10.1001/jama.2018.12512 - DOI - PMC - PubMed
    1. Barrett J. S., Patel D., Dombrowsky E., Bajaj G., Skolnik J. M. (2013). Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients. AAPS J. 15, 775–786. 10.1208/s12248-013-9489-z - DOI - PMC - PubMed